Concord Drugs Ltd
Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on
approved formulations
- Market Cap ₹ 85.0 Cr.
- Current Price ₹ 85.0
- High / Low ₹ 92.5 / 26.1
- Stock P/E 160
- Book Value ₹ 34.4
- Dividend Yield 0.00 %
- ROCE 4.73 %
- ROE 0.88 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -6.38% over past five years.
- Company has a low return on equity of 1.66% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.95 | 40.02 | 50.68 | 57.43 | 51.80 | 48.08 | 51.34 | 51.33 | 58.96 | 51.31 | 43.26 | 36.93 | 42.18 | |
| 30.72 | 32.99 | 42.38 | 51.93 | 47.02 | 44.43 | 48.00 | 48.11 | 53.37 | 46.97 | 39.58 | 33.16 | 37.98 | |
| Operating Profit | 3.23 | 7.03 | 8.30 | 5.50 | 4.78 | 3.65 | 3.34 | 3.22 | 5.59 | 4.34 | 3.68 | 3.77 | 4.20 |
| OPM % | 9.51% | 17.57% | 16.38% | 9.58% | 9.23% | 7.59% | 6.51% | 6.27% | 9.48% | 8.46% | 8.51% | 10.21% | 9.96% |
| 0.12 | 0.37 | 0.15 | 0.09 | 0.14 | 0.09 | 0.12 | 3.86 | 0.10 | 0.01 | 0.01 | 0.01 | 0.00 | |
| Interest | 1.78 | 2.72 | 2.57 | 2.36 | 1.88 | 1.59 | 1.54 | 1.42 | 1.68 | 1.62 | 1.59 | 1.72 | 1.78 |
| Depreciation | 1.14 | 3.63 | 2.91 | 2.58 | 2.40 | 1.71 | 1.46 | 1.37 | 1.76 | 1.60 | 1.54 | 1.42 | 1.45 |
| Profit before tax | 0.43 | 1.05 | 2.97 | 0.65 | 0.64 | 0.44 | 0.46 | 4.29 | 2.25 | 1.13 | 0.56 | 0.64 | 0.97 |
| Tax % | 20.93% | 33.33% | 40.74% | 73.85% | 50.00% | 9.09% | 28.26% | 23.54% | 28.89% | 21.24% | 25.00% | 54.69% | |
| 0.34 | 0.70 | 1.75 | 0.16 | 0.32 | 0.41 | 0.33 | 3.28 | 1.59 | 0.89 | 0.42 | 0.30 | 0.53 | |
| EPS in Rs | 0.47 | 0.97 | 2.42 | 0.22 | 0.41 | 0.52 | 0.38 | 3.75 | 1.82 | 0.96 | 0.42 | 0.30 | 0.53 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -6% |
| 3 Years: | -14% |
| TTM: | -7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -2% |
| 3 Years: | -43% |
| TTM: | 200% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 31% |
| 3 Years: | 38% |
| 1 Year: | 132% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.24 | 7.24 | 7.24 | 7.24 | 7.86 | 7.86 | 8.74 | 8.74 | 8.74 | 9.32 | 10.00 | 10.00 | 10.00 |
| Reserves | 7.33 | 6.07 | 7.82 | 11.75 | 11.46 | 15.29 | 14.74 | 18.02 | 19.62 | 22.38 | 23.82 | 24.11 | 24.42 |
| 17.31 | 21.27 | 19.99 | 15.43 | 13.62 | 9.83 | 9.57 | 12.97 | 16.43 | 15.63 | 14.93 | 16.91 | 14.89 | |
| 12.80 | 19.63 | 17.44 | 21.11 | 73.48 | 49.79 | 24.96 | 10.15 | 11.66 | 9.31 | 7.55 | 7.56 | 12.87 | |
| Total Liabilities | 44.68 | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 58.58 | 62.18 |
| 20.84 | 18.32 | 15.18 | 13.64 | 13.51 | 11.85 | 10.52 | 13.83 | 13.97 | 12.86 | 11.63 | 12.17 | 11.48 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 1.00 | 0.00 | 0.55 | 0.92 | 1.63 | 2.00 | 2.05 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42 | 1.62 | 1.62 | 1.62 |
| 23.84 | 35.89 | 37.31 | 41.89 | 92.91 | 70.63 | 46.49 | 36.05 | 41.93 | 41.44 | 41.42 | 42.79 | 47.03 | |
| Total Assets | 44.68 | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 58.58 | 62.18 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.28 | 1.75 | 3.05 | 1.70 | 6.88 | 1.19 | 2.48 | 1.62 | 0.77 | 2.24 | 1.96 | 3.16 | |
| -2.14 | -1.10 | 0.23 | -1.04 | -2.21 | -0.34 | -0.84 | -3.67 | -2.44 | -2.27 | -1.21 | -2.32 | |
| -0.17 | -0.70 | -3.42 | -3.94 | -4.80 | -0.73 | -1.79 | 2.07 | 1.68 | 0.05 | -0.69 | -0.87 | |
| Net Cash Flow | -0.03 | -0.06 | -0.14 | -3.28 | -0.13 | 0.12 | -0.15 | 0.02 | 0.01 | 0.03 | 0.06 | -0.02 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 180.83 | 249.90 | 183.51 | 99.46 | 501.49 | 367.66 | 180.94 | 147.41 | 141.52 | 116.31 | 117.87 | 125.22 |
| Inventory Days | 65.28 | 65.82 | 76.39 | 87.31 | 156.96 | 171.81 | 140.84 | 100.83 | 151.64 | 156.25 | 202.72 | 252.62 |
| Days Payable | 140.64 | 207.64 | 92.05 | 129.50 | 559.47 | 393.02 | 109.72 | 26.76 | 62.25 | 45.98 | 35.17 | 45.03 |
| Cash Conversion Cycle | 105.47 | 108.09 | 167.85 | 57.27 | 98.98 | 146.44 | 212.05 | 221.48 | 230.90 | 226.58 | 285.41 | 332.82 |
| Working Capital Days | 55.48 | 68.04 | 113.14 | 4.00 | 79.27 | 102.33 | 103.37 | 140.30 | 112.48 | 145.12 | 126.56 | 134.22 |
| ROCE % | 7.15% | 11.35% | 16.06% | 8.67% | 7.48% | 6.16% | 6.06% | 5.36% | 9.30% | 5.97% | 4.48% | 4.73% |
Documents
Announcements
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 25 Nov
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 25 Nov
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 25 Nov
-
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
24 Nov - Preferential allotment on 20-11-2025: promoters allotted equity shares and warrants, increasing holdings.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
22 Nov - New Paper publication of financial results for Quarter and Half year ended 30 Sep,2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Product Portfolio:[1]
a) Pharmaceutical Ready to fill Pellets
b) Multiple Unit Pellet System (MUPS)
c) Tissue Bio Adhesive
d) Injectables (Small Volume Parenterals)
e) Oral Solid Dosages (Tablets & Capsules)
f) Liquid Orals (Syrups & Suspensions)
g) Dry Syrup (Powder)